Suzuki et al 2 Erythropoietin (EPO) is an essential growth factor for red blood cell (RBC) production, and it is mainly produced by renal EPO-producing (REP) cells in the kidneys in an anemia/hypoxia-inducible manner. 1,2 Erythropoiesis-stimulating agents (ESAs), including recombinant human EPO (rHuEPO), have been used to treat EPO-deficiency anemia in kidney disease patients for a quarter century. 3,4 Due to the short plasma half-life of rHuEPO (approximately 1 day after subcutaneous injection), renal anemia patients require rHuEPO injections every 2 or 3 days to maintain their RBC count at non-anemic levels. ISAM exhibit severe normocytic-normochromic anemia due to the loss of renal EPO production. 5 The EPO-deficiency anemia in ISAM begins approximately 2 weeks after birth, when the major site of EPO production switches from the liver to the kidneys. 5,6 We first confirmed that the hematocrit values and hemoglobin concentrations Suzuki et al 3 in the peripheral blood of ISAM were decreased to half of those in control mice at 4 weeks of age (Online Supplementary Figure S1A ). Iron concentrations in the serum and liver of ISAM were higher than those in control mice, suggesting that iron usage for erythropoiesis was suppressed due to anemia in ISAM. Consistently, the unsaturated iron binding capacity of transferrin (UIBC) in the peripheral blood was decreased, and the serum level of hepcidin, a peptide hormone that inhibits iron entry into circulation, 7.8 was increased in ISAM. Additionally, we found that EPO deficiency seems to be indirectly related to both systemic hypoxia and cardiomegaly through chronic severe but not in the bone marrow and spleen 48 hours after administration ( Figure 1C ). These data suggest that EPO gradually and persistently suppresses hepatic hepcidin production through the quick and transient induction of erythroblastic erythroferrone production because rHuEPO decreases the elevated hepcidin levels in ISAM on day-2 and day-3 but not at 6 hours after administration (see Figure 1C) . Although the mechanism of erythroferrone-mediated hepcidin suppression is unknown, the efficacies of shorter half-life ESAs on hepcidin suppression are weaker than that of C.E.R.A. by the single-dose injection.
Erythropoietin (EPO) is an essential growth factor for red blood cell (RBC) production, and it is mainly produced by renal EPO-producing (REP) cells in the kidneys in an anemia/hypoxia-inducible manner. 1, 2 Erythropoiesis-stimulating agents (ESAs), including recombinant human EPO (rHuEPO), have been used to treat EPO-deficiency anemia in kidney disease patients for a quarter century. 3, 4 Due to the short plasma half-life of rHuEPO (approximately 1 day after subcutaneous injection), renal anemia patients require rHuEPO injections every 2 or 3 days to maintain their RBC count at non-anemic levels. 3 Recently, long-acting ESAs, Darbepoetin alpha (DA, genetically modified EPO) and continuous EPO receptor (EPOR) activator (C.E.R.A., chemically modified rHuEPO), have been developed, with plasma half-lives of approximately 2 days and 5 days, respectively, after subcutaneous injection. 3, 4 Because of the lack of suitable animal models of EPO-deficiency anemia, it has been difficult to elucidate the detailed profiles of ESA-induced erythropoiesis in vivo. We recently generated a genetically modified mouse model of EPO-deficiency anemia, inherited super anemia mouse/mice (ISAM, Epo GFP/GFP :Tg 3.3K-EpoE3 genotype). 5 Using ISAM, we were able to obtain comparable measurements of the efficacies of 3 ESAs and demonstrated that the efficacies of these agents on erythropoiesis and iron metabolism depend on their plasma half-lives.
ISAM exhibit severe normocytic-normochromic anemia due to the loss of renal EPO production. 5 The EPO-deficiency anemia in ISAM begins approximately 2 weeks after birth, when the major site of EPO production switches from the liver to the kidneys. 5, 6 We first confirmed that the hematocrit values and hemoglobin concentrations in the peripheral blood of ISAM were decreased to half of those in control mice at 4 weeks of age (Online Supplementary Figure S1A ). Iron concentrations in the serum and liver of ISAM were higher than those in control mice, suggesting that iron usage for erythropoiesis was suppressed due to anemia in ISAM. Consistently, the unsaturated iron binding capacity of transferrin (UIBC) in the peripheral blood was decreased, and the serum level of hepcidin, a peptide hormone that inhibits iron entry into circulation, 7.8 was increased in ISAM. Additionally, we found that EPO deficiency seems to be indirectly related to both systemic hypoxia and cardiomegaly through chronic severe anemia in mature ISAM (Online Supplementary Figure S1B , C).
Three representative ESAs (rHuEPO, DA and C.E.R.A.) were subcutaneously injected into ISAM at 3.0 µg of EPO-peptide weight per 1-kg body weight (BW), a comparable dose as in clinical use. Three days after single injections of each ESA (day-3), the hemoglobin and RBC concentrations in the peripheral blood of ISAM were increased, as were the mean corpuscular volume (MCV) of RBCs and the weight of the spleen, the major site of EPO-inducible erythropoiesis in mice ( Figure 1A ). 9 These data indicate that these 3 ESAs similarly induce erythropoiesis in ISAM on day-3. Although C.E.R.A. further increased the levels of hemoglobin and RBC during the last 4 days of observation, the erythropoietic effects of rHuEPO or DA were eliminated on day-7
( Figure 1A) . Thus, the profiles of erythropoietic induction by ESAs largely depend on their plasma half-lives.
The elevated concentration of serum hepcidin in ISAM was strongly decreased to levels less than those in normal mice on day-3 ( Figure 1B ). At day-7, C.E.R.A. continued to suppress hepcidin levels, whereas hepcidin levels re-increased in ISAM injected with DA or rHuEPO. The circulating hepcidin concentration is fundamentally regulated at the gene (Hamp) transcription level in hepatocytes. 7, 8, 10 Each ESA significantly suppressed Hamp mRNA expression in ISAM livers 48 hours after administration ( Figure 1C ). At 6 hours after administration, C.E.R.A. dramatically decreased Hamp mRNA levels, whereas rHuEPO or DA administration did not change the induced Hamp levels. Hepatic Hamp expression is strongly suppressed by erythroferrone, which is secreted by erythroblasts immediately after EPO stimulation. 7, 11 In the hematopoietic organs of ISAM, erythroferrone (Fam132b) gene expression was induced in 6 hours after C.E.R.A. administration, and the induced levels were maintained 48 hours after administration ( Figure 1C ). DA administration induced Fam132b mRNA expression in the bone marrow of ISAM 6 and 48 hours after administration, suggesting different organ distributions of ESAs. In fact, rHuEPO induced Fam132b expression in the bone marrow of ISAM 6 hours after administration but not in the bone marrow and spleen 48 hours after administration ( Figure 1C ). These data suggest that EPO gradually and persistently suppresses hepatic hepcidin production through the quick and transient induction of erythroblastic erythroferrone production because rHuEPO decreases the elevated hepcidin levels in ISAM on day-2 and day-3 but not at 6 hours after administration (see Figure 1C) . Although the mechanism of erythroferrone-mediated hepcidin suppression is unknown, the efficacies of shorter half-life ESAs on hepcidin suppression are weaker than that of C.E.R.A. by the single-dose injection.
The hemoglobin levels of ISAM was continuously increased for 7 days after administration, and the increased level was maintained for an additional 7 days ( Figure   2A ). Indeed, fixed-point images of the ISAM back skin showed that the thin blood vessels of ISAM were filled with RBCs on day-7 ( Figure 2B ). Because both the MCV and spleen weights returned to the basal levels of the untreated ISAM at day-10 ( Figure   2A ), we concluded that C.E.R.A. continuously stimulates erythropoiesis for one week after administration.
C.E.R.A. dramatically reduced serum iron concentrations to the level of normal mice at day-3 ( Figure 2A ). Because of the rapid reduction in serum iron concentrations, the UIBC of ISAM was higher than that of control mice on day-3 and day-7. The altered levels of both serum iron and UIBC returned to untreated-ISAM levels on day-7. The accumulated iron in the spleens and livers of ISAM were decreased on day-3 and day-7, respectively ( Figure 2A ). Berlin blue staining also revealed decreased iron deposits in the ISAM spleens on day-7 ( Figure 2C ). Because the splenic iron was used before the hepatic iron was used, local splenic iron storage may be predominantly utilized for erythropoiesis instead of hepatic iron. The reduced serum hepcidin concentrations and hepatic Hamp mRNA expression in ISAM treated with C.E.R.A. were comparable to those of control mice between day-3 and day-7 and re-increased to their original levels at day-14 (Figure 2A ).
We then investigated the cardiomegaly and systemic hypoxia in ISAM after C.E.R.A. administration. ISAM hearts were enlarged due to severe anemia at 12 weeks of age, and C.E.R.A. administration decreased the size and weight within 7 days ( Figure 3A ,B). The anemia phenotype was reversed 28 days after a single dose of C.E.R.A.
(Online Supplementary Figure S2A) , and cardiomegaly developed again in ISAM ( Figure 3C ). These data indicate that severe anemia reversibly causes cardiomegaly in mice. A systemic hypoxic milieu emerged as a result of the severe anemia in ISAM, and the expression levels of the hypoxia-inducible genes Egln3 and Slc2a3 12 were significantly higher in the hearts and kidneys, respectively, of vehicle-treated ISAM than in those of the control mice ( Figure 3D ). The induced gene expression levels were reduced to the levels of control mice on day-10 ( Figure 3D ). These therapeutic effects were similarly observed in rHuEPO-treated ISAM when the hemoglobin level was increased to the normal range by 4-time injections for 7 days (Online Supplementary Figure S3 ). 
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Methods
Mice
Inherited with the C57Black/6 strain more than 6 times, and male mice were used for experiments.
In the ISAM-REC mice, a GFP cDNA is homozygously knocked into the Epo gene 
Blood analysis
Peripheral blood (0.2-0.3 mL) was collected from the mouse heart or submandibular vein into a 1.5-mL tube containing 5.0 µL of 0.5 M EDTA. To measure long-term changes of the hematocrit values in living mice, approximately 60 µL of peripheral blood was taken weekly from the tail using a heparinized microtube (Drummond) followed by centrifugation. The effect of this weekly small-volume phlebotomy was negligible.
Measurement of iron indices
Serum iron levels were measured using an automatic biochemistry analyzer (TBA-2000FR, Toshiba). Serum hepcidin levels were measured by a sensitive liquid chromatography/electrospray ionization tandem mass spectrometry method using a Triple
Quad 5500 system (AB Sciex) equipped with a Prominence UFLCXR system (Shimadzu)
as previously reported (the lower limit of quantitation is 10 ng/mL). 3, 4 The hepatic and splenic iron contents were measured via inductively coupled plasma atomic emission spectroscopy using an Optima 8000 spectrometer (PerkinElmer).
Erythropoiesis stimulating agents (ESAs)
rHuEPO ( 
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was extracted using ISOGEN (Nippon Gene). cDNAs was synthesized using a SuperScript III system (Invitrogen). Quantitative PCR (qPCR) was performed with the primers listed in Table 1 using the FastStart reagent (Roche). Hprt mRNA expression levels were used as an internal control for the qPCR experiments.
Dorsal chamber window and surface PO 2 measurement
A dorsal chamber window was prepared in the mouse back skin as previously described. 7, 8 To monitor the oxygen concentration inside the back skin, oxygen sensor foil (PreSens, Germany) was placed between the hole and the cover glass, and the surface oxygen tension was measured using a VisiSens A1 detector camera and imaging software (PreSens).
9
Histological analyses
Heart size was measured as the maximum width using a slide caliper. Sections (4 μm thickness) were prepared from paraffin-embedded formalin-fixed organs. Hemosiderin deposition was assessed using Berlin blue staining. 3 The heart sections were stained with hematoxylin-eosin (Muto). To detect fluorescent protein expression, frozen kidney sections (10 µm thickness), which were fixed in 4% paraformaldehyde for 4 hours at 4 ºC, were observed after DAPI counterstaining using a BZ9000 microscope (Keyence).
Statistics
The data are presented as the means ± standard deviation (SD). The P values were calculated using two-tailed, unpaired Student's t tests. Dunnett's test or the nonparametric Steel test were also used for multiple comparison. 
